Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety
Authors:
- 1 January 2017
- journal article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 29 (1) , 10-16
Abstract
This study assesses the efficacy, accessibility, and safety of hepatitis C virus (HCV) treatment in a safety net hospital population. Patients at Denver Health receiving pegylated interferon for HCV infection between 2008 and 2012 were included in this retrospective study. Sociodemographic, biochemical, and virologic data were collected on each patient. The primary outcomes were the rate of sustained virologic response and early treatment discontinuation, with reason for discontinuation documented. Multivariable analyses were performed to identify factors associated with the primary outcomes. Detectable HCV antibodies were found in 2912 patients, and 1630 had a detectable viral load. Eighty percent of these patients were uninsured/underinsured. Only 46% were seen in the hepatology clinic, and 8% received interferon-based HCV treatment. Of the 125 patients treated with interferon-containing regimens, 54% had genotype 1 infection. The overall rate of sustained virologic response (SVR) was 47%. Rapid virologic response, low FIB-4 score combined with age, and increasing number of days on therapy were associated with SVR in multivariable analysis. Therapy was prematurely discontinued in 43% of patients related to being lost to follow-up (30%), null response (24%), and intolerance to pegylated interferon/ribavirin (24%). Genotype 1 infection and unfavorable viral kinetics were associated with premature treatment discontinuation in multivariable analysis. There were no statistically significant associations between age, sex, ethnicity, race, diabetes, BMI, psychiatric comorbidities, income, employment status, homelessness, or insurance status and the primary outcomes. An acceptable SVR rate is achievable in a safety net patient population. Addressing the barriers to care will be paramount when using direct-acting antivirals.Keywords
This publication has 28 references indexed in Scilit:
- Toward a more accurate estimate of the prevalence of hepatitis C in the United StatesHepatology, 2015
- World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinomaHepatology, 2015
- Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans AffairsEpidemiologic Reviews, 2015
- Epidemiology of Hepatitis C Virus in Pennsylvania State Prisons, 2004–2012: Limitations of 1945–1965 Birth Cohort Screening in Correctional SettingsAmerican Journal of Public Health, 2014
- Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver DiseaseTransplantation, 2013
- Hepatitis C virus infection in USA: an estimate of true prevalenceLiver International, 2011
- Sociodemographic Trends in National Ambulatory Care Visits for Hepatitis C Virus InfectionDigestive Diseases and Sciences, 2008
- Hepatitis C Virus Infection among Prisoners in the California State Correctional SystemClinical Infectious Diseases, 2005
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and CirrhosisNew England Journal of Medicine, 2000
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000